BCG immunotherapy for superficial bladder cancer: An overview of the past, the present and the future

EAU Update Series

Volumn 1, Issue 2, 2003, Pages 80-86

  Van Der Meijden, Adrian P ^a   Sylvester, Richard J ^b  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

Author keywords

BCG immunotherapy; Efficacy; maintenance therapy; Intravesical therapy; Superficial bladder cancer; Toxicity

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ANTINEOPLASTIC ACTIVITY; BCG VACCINATION; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CORRELATION ANALYSIS; CYSTITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INSTILLATION; FEVER; FOLLOW UP; FUTUROLOGY; HUMAN; INFLAMMATION; META ANALYSIS; PROBABILITY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; SUPERFICIAL CANCER; TOXICITY; TRANSURETHRAL RESECTION; VIRUS STRAIN; VIRUS VIRULENCE;

EID: 15744394828     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9124(03)00016-3     Document Type: Article

References (34)

1. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3.
2. Lamm DL, van der Meijden APM, Akaza H, Brendler CB, Hedlund PO, Mizutani Y, et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995;2(Suppl 2):23-35.
3. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MKB, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 1996;156:1934-41.
4. Guerin C. The history of BCG. In: Rosenthal SR, editor. BCG vaccine: tuberculosis-cancer. Littleton (MA): PSG Publishing Co. Inc.; 1980, p. 35-43.
5. Pearl R. Cancer and tuberculosis. Am J Hyg 1929;9:97.
6. Rosenthal SR. Focal and general tissue responses to an avirulent tubercle bacillus (BCG) intracardiac route. Arch Pathol 1936;22:348.
7. Zbar B, Rapp HJ. Immunotherapy of guinea pig cancer with BCG. Cancer 1974;34:1532-40.
8. Bohle A, Thanhauser A, Ulmer AJ, Ernest M, Flad HD, Jocham D. Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG activated killer (BAK) cell phenomenon. J Urol 1993;150:1932-7.
9. Zlotta AR, Drowart A, van Vooren JP, Decock M, Pirson M, Palfliet K, et al. Evolution and clinical significance of the T-cell proliferative and cytokine response directed against the Fibronectin binding antigen 85 complex of bacillus Calmette-Guérin (BCG) during intravesical treatment of superficial bladder cancer. J Urol 1997;157:492-8.
10. van der Meijden A. Bacillus Calmette-Guérin (BCG) for transitional cell carcinoma of the bladder. In: Hall RR, editor. Clinical management of bladder cancer. London: Arnold; 1999, p. 125-147.
11. Herr HW, Pinsky CM, Whitmore WF, Oettgen HF, Melamed MR. Effect of intravesical bacillus Calmette-Guérin (BCG) on carcinoma in situ of the bladder. Cancer 1983;51:1323-6.
12. Luftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, et al. Intravesical versus intravesical plus interdermal bacillus Calmette-Guérin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996;155:483-7.
13. Brosman S. Experience with bacillus Calmette-Guérin in patients with superficial bladder cancer. J Urol 1982;128:27-30.
14. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209-16.
15. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5.
16. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Algaba F, Vicente-Rodriquez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;163:680-4.
17. Oosterlinck W, Kurth KH, Schröder FH, Bultinck J, Hammond B, Sylvester R and members of the European Organization for Research and Treatment of Cancer Genitourinary Group. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149:749-752.
18. Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C, The EAU Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002;41:105-12.
19. Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
20. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guérin immunotherapy in 1,278 patients with bladder cancer. J Urol 1986;135:272-4.
21. Lamm DL, van der Meijden APM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
22. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000;163:1124-9.
23. van der Meijden APM, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guérin., and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder. A European Organization for Research and Treatment of Cancer GU Group randomized phase III trial. J Urol 2001;166:476-81.
24. van der Meijden APM, Sylvester R, Oosterlinck W, Casetta G, Hoeltl W, Bono A. Maintenance bacillus Calmette-Guérin for Ta T1 bladder cancer is not associated with increased toxicity. Results from an EORTC Genito-Urinary Group phase III trial. Eur Urol Suppl 2003;2(1):190 [Abstract 751].
25. Saint F, Irani J, Patard J, Salmon L, Hoznek A, Zammato S, et al. Tolerability of bacilli Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 2001;57:883-8.
26. Morgia G, Falsperla M, Madonia M, Vacirca F, La Pira G, De Grande G, et al. Use of BCG in immunotherapy of superficial bladder cancer: multicentric investigation on safety and compliance. UroOncology 2002;2(3):129-35.
27. Orihuela E, Herr HW, Pinsky CM, Whitmore WF. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987;60:326-33.
28. Saint F, Patard J, Irani J, Salomon L, Hoznek A, Legrand P, et al. Leukocyturia as a predictor of tolerance and efficacy of intavesical BCG maintenance therapy for superficial bladder cancer. Urol 2001;57:617-22.
29. Sylvester R, van der Meijden APM, Oosterlinck W, Casetta G, Hoeltl W, Bono A. The side effects of bacillus Calmette-Guérin in the treatment of Ta T1 bladder cancer do not predict its efficacy. Results from an EORTC Genito-Urinary Group phase III trial. Eur Urol Suppl 2003;2(1):191 [Abstract 753].
30. Martinez-Pineiro JA, Flores N, Isorna S, Solsona E, Sebastian JL, Pertusa C, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89:671-80.
31. Mack D, Höltl W, Bassi P, Brausi M, Ferrari P, de Balincourt C, et al., Members of the EORTC GU Group. The ablative effect of quarter dose bacillus Calmette-Guérin on a papillary marker lesion of the bladder. J Urol 2001;165:401-3.
32. Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, et al. What is the optimal regimen for BCG intravesical therapy? Eur Urol 2000;37:470-7.
33. Lamm DL. Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 1985;134:40-7.
34. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 1987;5:441-9.